Global medical technology company
Medtronic plc
Medtronic earns revenue from cardiovascular, neuroscience, surgical and endoscopy, patient monitoring, and diabetes technologies. It sells to healthcare providers and public procurement bodies directly or through distributors, while paying for precision components, OEM manufacturing, and continuous glucose monitoring sensors. Acquisitions and externally funded research programs also extend its portfolio.
MDT Updated Sep 11, 2026 3 AI consumers· 2 recurring
Per the valuechain.wiki graph, Medtronic plc is directly linked to 2 companies (1 supply, 0 revenue, 1 investment relationships) and reaches 6 companies within two hops; the links are backed by 9 dated sources, 4 of them primary filings (as of 2026-09-11).
Financials & Segments
- Total revenue · FY2026 net sales of $36.364 billion for the year ended April 24, 2026
- Segments · Cardiovascular · Neuroscience · Medical Surgical · Diabetes · Other and adjustments
Revenue from
- Vizient, Inc. Medium confidence
Medtronic contracted to add Touch Surgery Enterprise to Vizient's offerings. Vizient provides access to more than half of U.S. acute care providers, but counterparty-specific revenue was not disclosed.Confirms EN Medtronic Published Mar 9, 2022: Medtronic Announces Contract with Vizient for Touch Surgery Enterprise - Premier, Inc. Medium confidence
Premier's 2025 vendor contract list names Medtronic entities in both Surgical PPI and CV PPI. The relationship spans major product groups through a national GPO channel, but counterparty-specific revenue was not disclosed.Confirms EN Premier, Inc. Published Apr 10, 2025: Premier Participating Vendor and Vendor Contract List
Pays to
- Integer Holdings Corporation High confidence· Revenue share 10 percent · FY2025 Integer · Disclosed lower bound of Medtronic's share of Integer's total sales
Integer is a contract development and manufacturing supplier of components and finished products for cardiac rhythm management, neuromodulation, and cardiovascular applications. Medtronic represented more than 10% of Integer's 2025 sales, but the exact share was not disclosed. - Acutus Medical, Inc. High confidence
Acutus Medical manufactures Medtronic's left-heart access product portfolio as an OEM supplier. It sells the products at specified transfer prices, but Medtronic's counterparty-specific purchases are not disclosed. - Abbott Laboratories High confidence
MiniMed, separated from Medtronic's diabetes business, purchases Abbott-manufactured exclusive CGM sensors under a formula-based per-unit payment. The agreement was signed in 2024 by a Medtronic subsidiary and MiniMed remained consolidated at FY2026 year-end, but this cost edge should move to MiniMed after full separation.Confirms KO Medical Times Korea Published Jun 8, 2026: MiniMed Expands Abbott Partnership After Leaving MedtronicConfirms EN Abbott Published Aug 7, 2024: Abbott Enters Global Partnership to Connect Its CGM System with Medtronic's Insulin Delivery Devices
Investors
- Blackstone High confidence· Amount $142M · FY2026 · FY2026 income recognized under Blackstone research and development funding arrangements
Blackstone Life Sciences affiliates fund development programs in Medtronic's cardiovascular and diabetes businesses. Medtronic recognized $142 million of income under these arrangements in FY2026.
Investments
- CathWorks Ltd. High confidence· Amount $525M · acquisition closed 2026-04-20 · Cash and contingent consideration transferred to acquire CathWorks' remaining equity
Medtronic acquired CathWorks' remaining equity in April 2026. The 10-K records $525 million of consideration transferred, comprising $410 million of cash and $115 million of contingent consideration.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Medtronic plc | node | -9.8 | -22.6 | +9.6 | +0.3 | +24 | -0.3 |
| Blackstone | benef1 | +107.1 | -40 | +82.7 | +35.1 | -7.8 | -8.9 |
| Abbott Laboratories | benef1 | +30.5 | -20.7 | +2.3 | +4.8 | +12.9 | -11.9 |
| Moderna | benef2 | +143.1 | -29.3 | -44.6 | -58.2 | -29.1 | +393.6 |
| Illumina | benef2 | +2.8 | -46.9 | -31.1 | -1.3 | -1.8 | +66.4 |
| CoreWeave | benef2 | · | · | · | · | · | +24.8 |
| Amazon | benef2 | +2.4 | -49.6 | +80.9 | +44.4 | +5.2 | +12 |
YTD as of 2026-09-04 · source: Yahoo Finance
Medtronic plc operates across Global medical technology company. It is -0.3% in 2026. The stock (-0.3%) and its supply side (avg -11.9%) are moving in step. Acquisitions and externally funded research programs also extend its portfolio.
Analysis generated from returns as of 2026-09-04